PDS Biotechnology
PDSB
37 hedge funds and large institutions have $8.01M invested in PDS Biotechnology in 2018 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 14 reducing their positions, and 9 closing their positions.
0.15% less ownership
Funds ownership: 1.71% → 1.56% (-0.15%)
14% less funds holding
Funds holding: 43 → 37 (-6)
27% less capital invested
Capital invested by funds: $11M → $8.01M (-$3.02M)
50% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 14
67% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTC
Ghost Tree Capital
New York
|
+$224K |
| 2 |
Two Sigma Advisers
New York
|
+$27.6K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$23.4K |
| 4 |
BFM
Boothbay Fund Management
New York
|
+$17.7K |
| 5 |
Renaissance Technologies
New York
|
+$15.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$401K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
-$186K |
| 3 |
DS
DRW Securities
Chicago,
Illinois
|
-$103K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$99K |
| 5 |
D.E. Shaw & Co
New York
|
-$87.1K |
PDSB Hedge Fund Activity: Q3 2018 in Review
37 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q3 2018, worth a combined $8.01M — down 27% from $11M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of PDSB and 3 opened new positions — a net loss of 6 holders — while 14 trimmed existing stakes and 7 added.
The largest buyer was Ghost Tree Capital, adding an estimated $224K. The largest seller was Millennium Management, cutting an estimated $401K.
- 37 institutional investors held PDS Biotechnology (PDSB) as of Q3 2018, down from 43 in Q2 2018.
- Funds reported $8.01M of PDS Biotechnology stock for Q3 2018, down 27% quarter-over-quarter.
- 3 funds opened new PDS Biotechnology positions in Q3 2018 and 9 closed out, a net change of -6 holders.
- The largest PDS Biotechnology buyer in Q3 2018 was Ghost Tree Capital, an estimated $224K added.
- The largest PDS Biotechnology seller in Q3 2018 was Millennium Management, an estimated $401K sold.
Based on aggregated 13F filings for Q3 2018.